Finance

Lists
Q2 2026 earnings • released • EPS beat +12.16% • Revenue beat +208,909.01%
See results
ALLO:NASDAQ
Allogene Therapeutics Inc
$2.05
+3.54%
(+0.070) 1D
$2.06
+0.49% (+0.0100)
After hours
Closed: Aug 14, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ALLO...
Open
$1.96
High
$2.08
Low
$1.92
Mkt. cap
708.26M
Avg. vol.
6.87M
Volume
4.61M
52-wk high
$4.46
52-wk low
$1.03
EPS
-$0.67
Beta
0.48
Shares outstanding
345.49M
No. of employees
150
Open
$1.96
High
$2.08
Low
$1.92
Mkt. cap
708.26M
Avg. vol.
6.87M
Volume
4.61M
52-wk high
$4.46
52-wk low
$1.03
EPS
-$0.67
Beta
0.48
Shares outstanding
345.49M
No. of employees
150
News stories
From web sources and news partners
About Allogene Therapeutics Inc
CEO-
Employees150
Founded2017
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websiteallogene.com
Analyst ratings
Based on 6 analysts giving stock ratings to ALLO in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for ALLO in the last 3 months.
Highest
Current $2.05
$14.00 (+582.93%)
Average
$10.25 (+400.00%)
Lowest
$8.00 (+290.24%)
Analyst
Recommendation
Action
Price target
Projected
Date
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
08/12/2026
Unknown Analyst
UBS
Buy
Reiterated
$8.00
+290.2%
08/13/2026
Luca Issi
RBC Capital
Buy
Reiterated
$9.00
+339%
08/12/2026
Biren Amin
Piper Sandler
Buy
Maintained
$10.00
+387.8%
08/13/2026
John Newman
Canaccord Genuity
Buy
Reiterated
$14.00
+582.9%
08/13/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
08/13/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
$7.00
+241.5%
05/14/2026
Brian Cheng
J.P. Morgan
Hold
Upgraded
-
-
04/16/2026
Roger Song
Jefferies
Buy
Maintained
$10.00
+387.8%
04/15/2026
Jack Allen
Robert W. Baird
Buy
Maintained
$9.00
+339%
04/14/2026
William Pickering
Bernstein
Hold
Maintained
$3.85
+87.8%
04/14/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$11.00
+436.6%
04/16/2026
Reni Benjamin
Citizens JMP
Buy
Maintained
$8.00
+290.2%
04/14/2026
Samantha Semenkow
Citi
Buy
Reiterated
$4.00
+95.1%
04/09/2026
Asthika Goonewardene
Truist Financial
Buy
Maintained
$10.00
+387.8%
03/13/2026
Last report
Aug 12, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.13 / -$0.15
+12.16%beat
Revenue / Est. (USD)
4.64M / 2.22K
+208,909.01%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
4.64M
Cost of goods sold
31.16M
28.63M
32.00M
30.72M
Cost of revenue
31.16M
28.63M
32.00M
30.72M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13.74M
13.77M
14.09M
20.84M
Operating expense
13.74M
13.77M
14.09M
20.84M
Total operating expenses
44.90M
42.40M
46.09M
51.56M
Operating income
-44.90M
-42.40M
-46.09M
-46.92M
Other non operating income
-81.00K
247.00K
212.00K
-61.00K
EBT including unusual items
-41.40M
-38.81M
-42.61M
-42.68M
EBT excluding unusual items
-41.40M
-38.81M
-42.61M
-42.68M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-41.40M
-38.81M
-42.61M
-42.68M
Net profit margin
-
-
-
-919.76%
Earnings per share
-0.19
-0.17
-0.18
-0.13
Interest and investment income
3.93M
3.66M
3.57M
4.65M
Interest expense
-344.00K
-313.00K
-300.00K
-343.00K
Net interest expenses
3.58M
3.35M
3.27M
4.30M
Depreciation and amortization charges
-
-
-
-
EBITDA
-41.80M
-39.35M
-43.22M
-44.28M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps